X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (739) 739
life sciences & biomedicine (695) 695
humans (671) 671
male (424) 424
female (412) 412
gastroenterology & hepatology (401) 401
middle aged (381) 381
adult (353) 353
antiviral agents - therapeutic use (267) 267
hepatitis c, chronic - drug therapy (258) 258
aged (243) 243
hepatitis c (236) 236
hepacivirus - genetics (224) 224
gastroenterology and hepatology (193) 193
hepatitis c virus (192) 192
drug therapy, combination (177) 177
treatment outcome (172) 172
genotype (166) 166
interferon-alpha - therapeutic use (165) 165
ribavirin - therapeutic use (138) 138
hepatitis (137) 137
hepatitis c, chronic - virology (132) 132
interferon (116) 116
recombinant proteins (113) 113
care and treatment (111) 111
hepacivirus - drug effects (111) 111
health aspects (108) 108
polyethylene glycols - therapeutic use (108) 108
rna, viral - blood (108) 108
abridged index medicus (103) 103
ribavirin (100) 100
antiviral agents - administration & dosage (97) 97
liver cirrhosis (96) 96
antiviral agents - adverse effects (95) 95
patients (92) 92
young adult (90) 90
analysis (86) 86
genetic aspects (84) 84
drug therapy (83) 83
infectious diseases (83) 83
antiviral agents (82) 82
hepatitis c - drug therapy (81) 81
liver (81) 81
virology (81) 81
liver diseases (80) 80
adolescent (78) 78
viral load (77) 77
cirrhosis (75) 75
interferon-alpha - administration & dosage (72) 72
prospective studies (69) 69
biological response modifiers (68) 68
hepatology (68) 68
infections (66) 66
aged, 80 and over (65) 65
virus diseases (63) 63
genotype & phenotype (62) 62
ribavirin - administration & dosage (62) 62
recombinant proteins - therapeutic use (60) 60
retrospective studies (60) 60
risk factors (60) 60
polyethylene glycols - administration & dosage (59) 59
pharmacology & pharmacy (57) 57
research article (57) 57
research (55) 55
digestive system diseases (53) 53
hepacivirus - isolation & purification (53) 53
mutation (53) 53
general & internal medicine (52) 52
interferon-alpha - adverse effects (51) 51
medicine, general & internal (51) 51
ribavirin - adverse effects (51) 51
medicine (50) 50
oncology (50) 50
time factors (49) 49
alanine transaminase - blood (48) 48
genotypes (48) 48
hepatitis c - virology (48) 48
animals (47) 47
clinical trials (47) 47
double-blind method (46) 46
hepatitis c, chronic - complications (46) 46
oligopeptides - therapeutic use (46) 46
rna (46) 46
biochemistry & molecular biology (44) 44
immunology (44) 44
multidisciplinary sciences (44) 44
science & technology - other topics (44) 44
viruses (44) 44
hepatitis b, chronic - drug therapy (42) 42
antiviral agents - pharmacology (41) 41
microbiology (41) 41
dose-response relationship, drug (40) 40
prognosis (40) 40
chronic infection (39) 39
hepatitis c, chronic - blood (39) 39
drug administration schedule (38) 38
follow-up studies (38) 38
liver cancer (38) 38
viral nonstructural proteins - genetics (38) 38
medical research (37) 37
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Deutsches Ärzteblatt international, ISSN 1866-0452, 01/2017, Volume 114, Issue 1-2, pp. 11 - 21
Background: Among patients with chronic hepatitis C, 20-30% develop hepatic cirrhosis and its complications within 30 years. The antiviral treatment of... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Continuing Medical Education
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 12/2018, Volume 143, Issue 24, pp. 1784 - 1788
Was ist neu? Ziele der antiviralen Therapie  Ziel der individuellen antiviralen Therapie ist die dauerhafte Viruseradikation, populationsbezogen die... 
Klinischer Fortschritt
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898